News | Artificial Intelligence | June 13, 2019

iCAD Introduces ProFound AI for 2D Mammography in Europe

Company to showcase its newest artificial intelligence software solution at the SIFEM Medical Conference in France

iCAD Introduces ProFound AI for 2D Mammography in Europe

June 13, 2019 — iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to iCAD’s deep-learning, artificial intelligence (AI) platform and follows the launch of ProFound AI for Digital Breast Tomosynthesis (DBT), which was CE Marked in March 2018 and U.S. Food and Drug Administration (FDA)-cleared in December 2018. ProFound AI for 2D Mammography and ProFound AI for DBT will both be featured in the iCAD exhibition booth at the Société Française d'Imagerie de la FEMme (SIFEM) medical conference June 13-15, 2019, in Lille, France.

ProFound AI is available for both mammography and tomosynthesis modalities; it is a high-performance, deep-learning, breast cancer detection and workflow solution that offers benefits to radiologists and patients alike. ProFound AI for DBT is clinically proven to improve cancer detection rates by 8 percent, reduce unnecessary patient recall rates by 7.2 percent, and slash reading time for radiologists by 52.7 percent and up to 57.4 percent for dense breast 3-D image analysis.1

“The arrival of the ProFound AI platform has completely changed the way we read tomosynthesis cases. It is a very powerful and extremely useful tool that improves our diagnostic confidence; especially for subtle lesions and dense breasts,” according to Patrick Toubiana, M.D., radiologist, president and cofounder at the C.S.E. Centre Imagerie Médicale Numérique in Paris. “In addition, ProFound AI allows us to optimize our workflow for better reading comfort and a reduction of the interpretation time of the tomosynthesis slices. Today, ProFound AI is a real asset in our daily practice that we could not do without.”

ProFound AI for 2D Mammography and ProFound AI for DBT were designed to rapidly and accurately analyze each image. They provide radiologists with key information, such as certainty of finding lesion and case scores, which assists in clinical decision-making and prioritizing caseloads. Featuring the latest in deep learning AI, the platform also allows for continuously improved performance via ongoing updates.

ProFound AI for 2D Mammography is pending CE Mark in the EU.

For more information: www.icadmed.com

Related Content

FDA Clears iCAD's ProFound AI for Digital Breast Tomosynthesis

VIDEO: How iCad Uses AI to Speed Breast Tomosynthesis

 

Reference

Hoffmeister J. (2018). Artificial Intelligence for Digital Breast Tomosynthesis – Reader Study Results. [White paper]. Accessed June 4, 2019 via https://www.icadmed.com/assets/dmm253-reader-studies-results-rev-a.pdf

Related Content

A World Health Organization (WHO) rapid advice guide on the use of chest imaging in the diagnosis and management of COVID-19 was published in the journal Radiology.

Getty Images

News | Coronavirus (COVID-19) | July 30, 2020
July 30, 2020 — A World Health Organization (WHO) rapid advice gui
It covers every major modality, including breast imaging/mammography, fixed and portable C-arms (cath, IR/angio, hybrid, OR), CT, MRI, nuclear medicine, radiographic fluoroscopy, ultrasound and X-ray
News | Radiology Imaging | July 29, 2020
July 29, 2020 — IMV Medical Information, part of Scien...
 The Radiological Society of North America (RSNA) has been awarded a $750,000 grant by the Department of Energy’s National Nuclear Security Administration (NNSA) to develop a Global Learning Center (GLC) in Sub-Saharan Africa. The grant will help address the growing need in Sub-Saharan Africa for training in radiology.
News | Radiology Education | July 28, 2020
July 28, 2020 — The Radiological Society of North America (RSNA)
Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

Prostate biopsy with cancer probability (blue is low, red is high). This case was originally diagnosed as benign but changed to cancer upon further review. The AI accurately detected cancer in this tricky case. Image courtesy of Ibex Medical Analytics

News | Prostate Cancer | July 28, 2020
July 28, 2020 — A study published in 
Zebra Medical Vision announced its sixth FDA 510(k) clearance for its mammography solution, HealthMammo, which has already received a CE mark. Zebra Medical’s algorithm empowers breast radiologists by prioritizing and identifying suspicious mammograms, providing a safety net for radiologists. The suspicious mammograms are identified faster and read earlier than the current “first-in first-out” standard of care. 
News | Breast Imaging | July 27, 2020
July 26, 2020 —  Zebra Medical Vision announced its sixth FDA 510
RSNA 2020: Human Insight/Visionary Medicine, will be held as an all-virtual event, Nov. 29 – Dec. 5, 2020
News | RSNA | July 22, 2020
July 22, 2020 — Registration is now open for the Radiological Society of North America (...